（文章来源：证券日报） 证券日报网讯 12月9日晚间，诚意药业发布公告称，近日，公司收到国家药品监督管理局核准签发的托 拉塞米片《药品注册证书》（证书编号：2025S03607、2025S03608），并视同通过仿制药一致性评 价。 ...

格隆汇12月9日丨诚意药业(603811.SH)公布，公司收到国家药品监督管理局核准签发的托拉塞米片 （称"本品"）《药品注册证书》（证书编号：2025S03607、2025S03608），本品适用于治疗与心力衰 竭、肾脏疾病或肝脏疾病相关的水肿。用于治疗高血压，本品可单独使用或者与其他抗高血压药物联合 使用。 ...

诚意药业公告称，近日收到国家药监局核准签发的托拉塞米片《药品注册证书》，规格为5mg、 10mg，注册分类为化学药品4类，视同通过仿制药一致性评价。该药品适用于治疗水肿和高血压，2024 年7月2日提交注册申请获受理。截至公告披露日，通过批准的厂家共6家，产品未纳入国家药品集中采 购目录。公司托拉塞米片研发投入1099.41万元。因医药产品特性，生产和销售或受不确定因素影响。 ...

截至发稿，诚意药业市值为35亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王瀚黎） 2024年1至12月份，诚意药业的营业收入构成为：医药制造业占比99.71%，其他业务占比0.29%。 每经AI快讯，诚意药业（SH 603811，收盘价：10.81元）12月9日晚间发布公告称，近日，浙江诚意药 业股份有限公司收到国家药品监督管理局核准签发的托拉塞米片《药品注册证书》。产品名称为"托拉 塞米片"。 ...

格隆汇12月9日丨诚意药业(603811.SH)公布，公司收到国家药品监督管理局核准签发的托拉塞米片 （称"本品"）《药品注册证书》（证书编号：2025S03607、2025S03608），本品适用于治疗与心力衰 竭、肾脏疾病或肝脏疾病相关的水肿。用于治疗高血压，本品可单独使用或者与其他抗高血压药物联合 使用。 ...

Group 1: Financial Performance - In 2024, the company's revenue was CNY 445,864,331.31, a decrease of 32.75% compared to the previous year [2][3] - The net profit attributable to shareholders was CNY 91,547,379.78, down 48.02% year-on-year [2][3] Group 2: Research and Development - In 2024, the company invested CNY 32,937,088.26 in R&D and reported one Chinese invention patent [2] - The company has obtained several drug registration certificates, including for ibuprofen sustained-release capsules and tolvaptan injection [3] Group 3: Future Plans - The company aims to reduce production costs and enhance market competitiveness through technological upgrades [3] - A new R&D center in Wuhan has been established to accelerate the development of a CDMO one-stop service platform [3] Group 4: Shareholder Engagement - The company currently has no plans for share buybacks but will disclose any future plans in accordance with regulations [2] - The company actively engages with investors through online platforms for Q&A sessions [2]

Group 1: Industry Outlook - The healthcare expenditure per capita in China for 2024 is projected to be CNY 2,547, accounting for 9.0% of total consumption, reflecting a 3.54% increase from CNY 2,460 in 2023, indicating steady growth in the pharmaceutical market [3]. Group 2: R&D Progress - The company has made significant advancements in its R&D projects, including the approval of the raw material drug Acetate Abiraterone and the successful completion of consistency evaluations for Torasemide tablets [3][4]. - Several products, including Ibuprofen sustained-release capsules and Arginine Ibuprofen raw materials, have received drug registration certificates, while others are in various stages of evaluation and approval [3]. Group 3: Impact of Tariff Policies - The average sales revenue from products exported to the U.S. over the past three years constitutes approximately 1% of total sales, suggesting that recent U.S. tariff policies have a limited direct impact on the company [4]. Group 4: Future Growth Drivers - The company plans to enhance performance through an integrated strategy for raw material and formulation, increased R&D investment, and improved efficiency in product development [4]. - The newly established Wuhan R&D center will support the creation of a comprehensive CDMO service platform, driving future growth [4]. - Cost reduction initiatives, including process optimization and lean production activities, are expected to enhance market competitiveness and production capacity [4]. Group 5: Financial Performance - The company has publicly disclosed its 2024 annual report and Q1 2025 report, with specific performance details available in related announcements [4]. - The company's sales expense ratio is positioned below the industry average, primarily allocated to sales personnel salaries, exhibition costs, travel expenses, and promotional activities [4].

Core Insights - The core viewpoint of the news is that Hendi Pharmaceutical experienced significant declines in revenue and profit in 2024, primarily due to reduced sales of its core product, ibuprofen raw materials, and low international market prices [2][4] Financial Performance - In 2024, Hendi Pharmaceutical achieved operating revenue of 445 million yuan, a year-on-year decrease of 32.75% [2] - The net profit attributable to shareholders was 91.54 million yuan, down 48.02% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 72.95 million yuan, a decline of 57.14% year-on-year [2] - Basic earnings per share were 0.32 yuan [2] Revenue Breakdown - The decline in operating revenue was mainly due to a decrease in sales volume of ibuprofen raw materials and low international market prices [4] - The raw materials segment generated revenue of 356 million yuan, accounting for 79.88% of total revenue [4] - The formulation segment contributed 85 million yuan, representing 19.11% of total revenue [4] Product Performance - Revenue from non-steroidal anti-inflammatory drugs (ibuprofen) was 317 million yuan, down 40.69% year-on-year, making up 71.15% of total revenue [4] - The cardiovascular segment saw revenue of 63.49 million yuan, a slight increase of 1.10% year-on-year, with stable performance from products like Torasemide tablets [4] R&D and Future Plans - R&D investment in 2024 was 32.94 million yuan, a decrease of 37.59% year-on-year, with the R&D expense ratio dropping to 7.39% [4] - The company added one new Chinese invention patent and several products entered the technical review stage [4] - The high-end pharmaceutical formulation internationalization project has been postponed to 2026, focusing on the coordinated development of raw materials and formulations [4]